Stefania Morganti, MD
@StefiMorganti
Research Fellow 👩🏼⚕️🧬 @DanaFarber | @Harvard l @BroadInstitute | From @IEOufficiale | @LaStatale 🇮🇹 Breast Cancer, Liquid Biopsy, ctDNA
Dr. Ana Garrido-Castro shared insights on #AntibodyDrugConjugates in #TNBC and Refractory ER+ #MetastaticBreastCancer highlighting new research on targeted delivery approaches. #HarvardBreastCancerCourse #MBC #ADCs
Dr. Marleen Kok (@lab_kok) delivered an excellent #HarvardBreastCancerCourse Schlager Lecture on #Immunotherapy in Early #BreastCancer. The Schlager lectureship brings in world leading cancer investigators working in women's cancers.
Dr. Olga Kantor (@OKantorMD) discussed the implications of the #SOUNDtrial, examining de-escalation strategies in #AxillarySurgery and outcomes in #BreastCancer patients. #HarvardBreastCancerCourse
The Axilla After Neoadjuvant Therapy: How Much is Too Much? - a great discussion on axillary management by Dr. Elizabeth Mittendorf (@EMittendorfMD) at the #HarvardBreastCancerCourse.
Dr. Guilherme Nader Marta (@GuiNaderMarta) discussed #Immunotherapy in #TNBC, reviewing key questions after KEYNOTE-522: ❔Is the adjuvant phase truly necessary in pts with pCR? ❔Can we omit #anthracyclines from the chemo backbone? What is the ideal chemo partner? ❔What if…
Check out this review on #ArtificialIntelligence entering the pathology arena in oncology: current applications and future perspectives 🔓pubmed.ncbi.nlm.nih.gov/40307127/ ✍️@antoniomarraMD @StefiMorganti @FresiaPareja @ThomasFuchsAI @Aparwani_dpath @curijoey @catemarchio
Amazing news! Congratulations Dr Mittendorf; a brilliant surgeon, scientist and colleague.
We’re proud to announce that Elizabeth Mittendorf, MD, will join BIDMC as Chief of a new Division of Breast Surgery! 👏 A renowned surgeon, she will bring bold leadership to our growing program in collaboration with Dana-Farber. Learn more: bidmc.org/about-bidmc/ne…
BRCA BCY global study with 1 ,865 BRCA mutations carriers with HR+ BC where @SUMAargentina participated actively provides evidence that OFS combined with ET improved DFS and OS @paolazagam @matteolambe #ASCO25
Amazing presentation by my senior Italian colleague @paolazagam on the impact of OFS with adjuvant ET on survival in young BRCA-mutated breast cancer pts. So proud to see female Italian oncologists thrive—huge thanks to all her mentors and her mentor abroad @DrLisaCarey 🙏🏻
Commitment,skills powered by supporting mentorship results in raising stars 🌟 pointing 👉 to the direction best #cancer care goes toward! RN at #ASCO24 Dr @paolazagam 🩺 showed how smart ideas within collaborative group & trust in young researchers can deliver better #bcsm care!
Thank you so much!!! 💪 #ASCO25
Excellent presentation by @paolazagam showing OFS + ET improved DFS and OS in a global cohort of young BRCA mutation carriers! Proud of you 👏🏼 👏🏼🤩 #ASCO25 #bcsm @OncoAlert @matteolambe
#ASCO25 #MetastaticBreastCancer Poster Session: Assessing the impact of #ScalpCooling in patients receiving #TrastuzumabDeruxtecan for metastatic #BreastCancer. @esalehiDNP Abs 1095 | Poster Bd 74 | Jun 2, 9-12 PM CDT | Hall A
Happening Now! #ASCO25 Poster Session 👉 Use of baseline plasma circulating tumor DNA (#ctDNA) to predict duration of endocrine therapy and CDK4/6 inhibitor therapy and to analyze intrinsic vs acquired #EndocrineResistance. @PietroDePlacido 📍Abs 1075 | Poster Bd 54 | Jun 2,…
A CURATIVE INTENT trial for de novo metastatic HER2 positive breast cancer. Why? Because the therapies are so good we think a portion of patients may be curable with intensive treatment instead of waiting for resistance to occur. It's bold but time to try.
The new #SAPPHO study, led by @DFCI_BreastOnc & @TheTBCRC, is evaluating a novel treatment approach for HER2+ #MetastaticBreastCancer. The study will help investigators understand if giving sequential treatments is safe and effective for patients with newly diagnosed HER2+ #MBC,…
The 1st edition of an international lung academy with a stellar faculty (clinicians and methodologists). Unmissable opportunity for early and mid-career investigators. Here how to apply forms.gle/etUvYaarjZNV2x… @mihaela_aldea @BiagioRicciutMD @MyUniSR @GustaveRoussy @DanaFarber
Check out the highlights video from the inaugural @_MDEducation #BreastCancer US Focus Meeting, chaired by Dr. Sara Tolaney (@stolaney1) and Dr. Virginia Kaklamani (@VKaklamani). The day was filled with outstanding presentations and dynamic panel discussions which you can now…
National Breast Cancer Coalition (@NBCCStopBC) issues a call to action on Medicaid, ACA cuts cancerletter.com/cancer-policy/…
Yes, in the metastatic setting. This is a great ref for this topic - pubmed.ncbi.nlm.nih.gov/39253462/ 18/21 #TumorBoardTuesday 👩🏻🏫Mini tweetorial 9👨🏻🏫 💻🌎 real-world data suggest ⬇️ benefit from CDK4/6i in gBRCA1/2 PV carrier 🧬 potential role of Rb1 loss
Great question and a good suggestion. If the patient had a BRCA reversion mutation, I would not favor a PARPi in this setting.
Given OS benefit, we favor olaparib over CDK4/6i for high-risk gBRCA carriers. For very high-risk pts, we recommend a sequential approach w/ olaparib first and CDK4/6i after. This is our algorithm (preceded ribo approval in this setting)